Sathe Nikhil, Beech Peter, Croft Larry, Suphioglu Cenk, Kapat Arnab, Athan Eugene
Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, Thane Belapur Road, Rabale, Navi Mumbai 400701, India.
School of Life and Environmental Sciences, Deakin University, Melbourne Burwood Campus, 221 Burwood Highway, Burwood Victoria 3125, Australia.
Infect Med (Beijing). 2023 May 26;2(3):178-194. doi: 10.1016/j.imj.2023.05.003. eCollection 2023 Sep.
is an aerobic Gram-negative rod-shaped bacterium with a comparatively large genome and an impressive genetic capability allowing it to grow in a variety of environments and tolerate a wide range of physical conditions. This biological flexibility enables the to cause a broad range of infections in patients with serious underlying medical conditions, and to be a principal cause of health care associated infection worldwide. The clinical manifestations of include mostly health care associated infections and community-acquired infections. possesses an array of virulence factors that counteract host defence mechanisms. It can directly damage host tissue while utilizing high levels of intrinsic and acquired antimicrobial resistance mechanisms to counter most classes of antibiotics. co-regulates multiple resistance mechanisms by perpetually moving targets poses a significant therapeutic challenge. Thus, there is an urgent need for novel approaches in the development of anti- agents. Here we review the principal infections caused by and we discuss novel therapeutic options to tackle antibiotic resistance and treatment of infections that may be further developed for clinical practice.
是一种需氧革兰氏阴性杆菌,具有相对较大的基因组和令人印象深刻的遗传能力,使其能够在各种环境中生长并耐受广泛的物理条件。这种生物学上的灵活性使该菌能够在患有严重基础疾病的患者中引起广泛的感染,并成为全球医疗保健相关感染的主要原因。该菌的临床表现主要包括医疗保健相关感染和社区获得性感染。该菌拥有一系列对抗宿主防御机制的毒力因子。它可以直接损害宿主组织,同时利用高水平的固有和获得性抗菌耐药机制来对抗大多数种类的抗生素。该菌通过不断移动靶点共同调节多种耐药机制,这带来了重大的治疗挑战。因此,迫切需要开发新型抗该菌药物的方法。在这里,我们综述了由该菌引起的主要感染,并讨论了应对抗生素耐药性的新型治疗选择以及可能进一步开发用于临床实践的该菌感染的治疗方法。
Microorganisms. 2023-3-31
Zhonghua Jie He He Hu Xi Za Zhi. 2022-8-12
Pathog Dis. 2013-3-15
Biotechnol Adv. 2018-11-27
Int J Med Microbiol. 2016-1
Expert Rev Anti Infect Ther. 2012-2
Drugs Context. 2018-5-29
Front Cell Infect Microbiol. 2025-6-30
Int J Mol Sci. 2025-7-5
World J Pediatr. 2025-6-3
Iran J Vet Res. 2025
Medicine (Baltimore). 2022-12-30
Access Microbiol. 2021-8-17
Case Rep Ophthalmol. 2021-4-12
Front Cell Infect Microbiol. 2021